The 15th Tumour Models Summit London is Europe's longest-standing and most comprehensive meeting dedicated to advancing preclinical and translational tumour modelling. As oncology pipelines become increasingly dependent on immunotherapies, cell therapies, ADCs, radioligand therapies, and precision medicines, development teams face growing pressure to improve translational confidence, identify predictive models, and generate decision-grade evidence earlier in development. Join leaders from Roche, AstraZeneca, Johnson and Johnson, Eli Lilly, Immunocore, Merck, Molecular Partners, ImmunoKey, and innovative oncology biotechs to explore how human-relevant models, NAMs, AI-enabled approaches, patient-derived systems, biomarkers, tumour microenvironment models, and integrated development strategies can improve candidate selection, predict clinical outcomes, and reduce late-stage attrition. Whether your focus is model validation, safety prediction, tumour microenvironment biology, translational biomarkers, AI-driven prediction, or regulatory strategy, this is the industry's definitive forum for improving oncology model translatability. Speakers: Adam Robertson, Chief Scientific Officer, Hemispherian, Alan Barge, Chief Executive Officer, 4C Biomed, Alaide Morcavallo, Senior Scientist, Research, Bioscience and Oncology, AstraZeneca, Andrew Whale, Director - Nonclinical Safety, Immunocore Ltd, Baldur Sveinbjornsson, Chief Scientific Officer, Lytix Biopharma AS, Claudio Murgia, Unit Head, Target and Disease Biology, Discovery Oncology, Roche, Frederic Pipp, Global Animal Welfare Officer and Director, EMEA and APAC, Merck KGaA, Himanshu Manchanda, Machine Learning Senior Scientist, Bayer, John Bridgeman, Chief Scientific Officer, Immunokey, Kuan-Chuan (Eric) Pao, Principal Scientist, Co-Founder, Outrun Therapeutics, Lenka Sadilkova, Director, Non-Clinical Projects Operations, Eli Lilly and Co., Martinus Capelle, Drug Product Development and Delivery, Distinguished Scientist, Johnson and Johnson, Moh Tadayyon, Co-founder, Apeikon Therapeutics, Monika Lamba Saini, Director, Medical, Translational, and Computational Pathology, GlaxoSmithKline, Phil Jakeman, Chief Executive Officer, MatchBio, Rocio Evangelista Vaz, Head, Preclinical Pharmacology, Molecular Partners, Romain Lara, Associate Director, AstraZeneca, Sara Colombetti, Senior Leader-Head of Translational Pharmacology, Roche, Sonja Gill, Director, Oncology Safety Combinations, Clinical Pharmacology and Safety Sciences, AstraZeneca, Victor Cortes, Head, Research, OneChain Immunotherapeutics

Description supplied by the event organiser.